arachidonoylcholine: structure in first source
arachidonoylcholine : An acylcholine obtained by formal condensation of the carboxy group of arachidonic acid with the hydroxy group of choline.
ID Source | ID |
---|---|
PubMed CID | 122198216 |
CHEBI ID | 133694 |
SCHEMBL ID | 22207934 |
MeSH ID | M0408944 |
Synonym |
---|
choline (5z,8z,11z,14z)-icosatetraenoate |
2-{[(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoyl]oxy}-n,n,n-trimethylethan-1-aminium |
choline (5z,8z,11z,14z)-eicosatetraenoate |
CHEBI:133694 |
(5z,8z,11z,14z)-eicosatetraenoylcholine |
(5z,8z,11z,14z)-icosatetraenoylcholine |
choline (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate |
choline arachidonate |
(5z,8z,11z,14z)-eicosa-5,8,11,14-tetraenoylcholine |
(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoylcholine |
choline (5z,8z,11z,14z)-eicosa-5,8,11,14-tetraenoate |
arachidonoylcholine |
SCHEMBL22207934 |
Role | Description |
---|---|
cholinergic agonist | Any drug that binds to and activates cholinergic receptors. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
acylcholine | A choline ester formed from choline and a carboxylic acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |